leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
|
9360930 |
1997 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that all human TEL/JAK2 fusion variants are oncoproteins in vitro that strongly activate STAT 5, and cause lethal myelo- and lymphoproliferative syndromes in murine bone marrow transplant models of leukemia.
|
9736611 |
1998 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently reported the involvement of ETV6-JAK2 fusion genes in the development of leukemia of both lymphoid and myeloid origin.
|
10449913 |
1999 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
TEL-JAK2 founder mice and their transgenic progeny developed fatal leukemia at 4 to 22 weeks of age.
|
10845925 |
2000 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fusion of the TEL gene on 12p13 to the JAK2 tyrosine kinase gene on 9p24 has been found in human leukemia.
|
11278610 |
2001 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aberrant activation of the JAK-STAT pathway has been implicated in tumor formation; for example, constitutive activation of JAK2 kinase or the enforced expression of STAT5 induces leukemia in mice.
|
15578097 |
2004 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
|
16557239 |
2006 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pre-TCR signaling synergizes with TEL-JAK2 to transform immature thymocytes and initiate leukemogenesis as shown by (1) the delayed leukemia onset in Rag2-, CD3epsilon- and pTalpha-deficient mice, (2) the occurrence of recurrent chromosomal alterations in pre-TCR-deficient leukemia, and (3) the correction of delayed leukemia onset in Rag2-deficient TEL-JAK2 mice by an H-Y TCRalphabeta transgene that mimics pre-TCR signaling.
|
17192390 |
2007 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01).
|
17229652 |
2007 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Moreover, JAK2 V617F mutations in CBF leukemias were associated with an aggressive clinical course with 80% of the patients relapsing.
|
17229652 |
2007 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia.
|
17851549 |
2008 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutively activated mutants of the non-receptor tyrosine kinases (TK) ABL1 (Abelson murine leukemia viral (v-abl) homolog (1) protein) and JAK2 (JAnus Kinase 2 or Just Another Kinase 2) play a central role in the pathogenesis of clinically and morphologically distinct chronic myeloproliferative disorders but are also found in some cases of de novo acute leukemia and lymphoma.
|
18528425 |
2008 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The only patient with non-Down's syndrome-associated leukaemia but with a JAK2 mutation had an isochromosome 21q.
|
18805579 |
2008 |
leukemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Essential thrombocythemia: past and present.
|
19636672 |
2009 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia.
|
19691103 |
2009 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tauhese results identify a previously unrecognized nuclear role for JAK2 in the phosphorylation of H3Y41 and reveal a direct mechanistic link between two genes, jak2 and lmo2, involved in normal haematopoiesis and leukaemia.
|
19783980 |
2009 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A search for additional mutations identified alterations of RUNX1, WT1, TP53, CBL, NRAS, and TET2, without significant differences between JAK2-mutant and wild-type leukemias.
|
20008300 |
2010 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the thrombopoietin receptor gene (myeloproliferative leukemia, MPL) have been reported in patients with JAK2 V617F-negative chronic myeloproliferative disorders (MPDs).
|
21326037 |
2011 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia.
|
21712540 |
2011 |
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the presence of mutations in the points most frequent for mutations (hotspot mutations) in phosphatidylinositol-3-kinase (PI3K), Janus kinase 2 (JAK2), FMS-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1), which are involved in leukemia and other cancers, in a population of Brazilian MDS patients.
|
21789382 |
2011 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study was conducted to investigate whether any association exists between genetic polymorphisms in the JAK2, STAT3 and STAT5 genes and individual susceptibility to leukemia.
|
22126101 |
2012 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Negative regulation of JAK2 by H3K9 methyltransferase G9a in leukemia.
|
22801367 |
2012 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Constitutive activation of Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling has an important role in the oncogenesis of myeloproliferative neoplasms (MPNs) and leukemia.
|
23111066 |
2013 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Continued research into how miRNAs impact JAK2(V617F) clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment.
|
23432162 |
2013 |
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We previously showed that CD34⁺/CD38⁻ acute myelogenous leukemia (AML) cells, which contain leukemia stem cells, expressed a greater amount of the phosphorylated forms of JAK2 and STAT5 (p-JAK2 and p-STAT5) than their CD34⁺/CD38⁺ counterparts.
|
23564444 |
2013 |